adult ovarian tissue leads to the formation of new oocytes, as determined by the detection of GFP-positive oocytes contained within follicles composed of host (wild-type, non-GFP) somatic granulosa cells 2, 3 . In mice, these oocytes are ovulated to produce mature, fertilizable eggs and viable offspring 2, 3, 24 . Although this complete developmental potential has yet to be shown using the equivalent human cells, human OSCs injected directly into adult human ovarian cortical tissue pieces transplanted into immunocompromised mice generate oocytes and participate in follicle formation in an in vivo environment 3 . These findings not only demonstrate the ability of adult human ovarian tissue to support folliculogenesis, but also they provide the first evidence that the ovarian follicle pool in women may, similar to that in mice, be amenable to renewal. Moving forward, the study of oogenesis in mammals, as well as the development of therapeutic strategies for the treatment of female infertility, should now take into account OSCs as natural precursor cells of oocytes 5, 6, 25 .
IntroDuctIon
The recent identification and isolation of OSCs (also referred to as fGSCs) from mouse and human ovaries has sparked both enthusiasm and controversy in the fields of reproductive biology, stem cell biology and clinical reproductive medicine [1] [2] [3] [4] [5] [6] . Although multiple lines of compelling evidence now exist that support the concept of postnatal oogenesis and follicle renewal in mammals, these new findings are at odds with what has become dogmatic thinking in the field for more than 5 decades (ref. 7) . To this day, age-related depletion of a 'fixed ovarian reserve' of oocytes endowed at birth remains a popular, if not convenient, means to explain why mammalian females undergo reproductive senescence approximately halfway through their chronological lifespan. However, after the initial challenge to this decades-old dogma 1 , work from many laboratories now strongly supports that the ovaries of mammals generate new oocytes and follicles during the reproductive period [1] [2] [3] [4] [5] [6] [8] [9] [10] [11] [12] .
Circumstantial evidence for the existence of OSCs
The field of OSC biology actually arose serendipitously from oocyte-counting experiments in mice, which were not originally designed to test whether oogenesis ceases before birth. Simply by asking whether the net decline in the number of healthy oocytecontaining follicles during postnatal life was paralleled by the detection of an equivalent number of dying oocytes over the same time period, a mathematical dilemma was uncovered that could not be solved under the constraints of the prevailing dogma. The incidence of oocyte loss through follicle atresia, assessed directly by scoring degenerative oocytes in serial ovarian sections, far exceeded the net decline in the ovarian reserve of oocytes in female mice as they transitioned from juvenile to adult life 1 . It was therefore logically concluded that this surprisingly high rate of oocyte loss during postnatal life must be partially offset by routine addition of new oocyte-containing follicles for ovarian function to persist as long as it does. Mathematical models were then used to estimate that mouse ovaries are replenished with ~77 new follicles per d, at least early in reproductive life 1 . This suggested that the oocyte progenitor cells responsible for oogenesis are either very rare or slow to proliferate. Either way, this model represents a striking departure from the thousands of spermatogonial stem cells (SSCs) and spermatogenic progenitor cells present in the testes of adult male mice that produce millions of spermatozoa daily [13] [14] [15] .
The presumed rarity of OSCs is in keeping with data showing that the germ cell-specific meiosis-commitment gene, Stra8 (stimulated by retinoic acid gene 8) (refs. 16,17) , which is abundantly expressed in adult testes and in embryonic ovaries during the period of oogenesis 18, 19 , is rare but not absent in ovaries of reproductive-age mice 8, 20 . Although the presence of these Stra8-expressing cells within adult ovaries is highly suggestive of ongoing de novo oocyte formation, recent genetic evidence further substantiates the occurrence of postnatal oogenesis and follicle renewal by demonstrating that the number of traceable mitotic divisions in oocytes of aged mice exceeds those in younger counterparts 21 . As oocytes themselves do not divide, the mitotic 'depth' of these cells reflects the number of mitoses that the progenitor germ cells underwent before production of a given oocyte at the time of analysis 22 . Coupled with the findings that unilateral ovariectomy in female mice at 1 month of age accelerates the mitotic depth in oocytes of the remaining ovary 3 months later, the simplest explanation for these findings is that the follicle pool is partly maintained during reproductive life by a relatively rare population of premeiotic germ cells capable of generating new oocytes that form follicles 21, 22 .
Purification of OSCs as proof of their existence
Over the past few years, several laboratories have independently reported the isolation of mammalian OSCs and their subsequent propagation in defined cultures 2, 3, 9, 23 . As expected of a rare pool of adult stem cells, the number of OSCs within the ovary is very low, representing ~0.014 ± 0.002% of the total ovarian cell population in adult female mice 3 . Cultivation of OSCs in vitro results in stable expansion of these premeiotic germ cells, as well as the spontaneous formation of immature oocytes 3, 9 . Furthermore, transplantation of ex vivo-expanded mouse or human OSCs expressing GFP into adult ovarian tissue leads to the formation of new oocytes, as determined by the detection of GFP-positive oocytes contained within follicles composed of host (wild-type, non-GFP) somatic granulosa cells 2, 3 . In mice, these oocytes are ovulated to produce mature, fertilizable eggs and viable offspring 2, 3, 24 . Although this complete developmental potential has yet to be shown using the equivalent human cells, human OSCs injected directly into adult human ovarian cortical tissue pieces transplanted into immunocompromised mice generate oocytes and participate in follicle formation in an in vivo environment 3 . These findings not only demonstrate the ability of adult human ovarian tissue to support folliculogenesis, but also they provide the first evidence that the ovarian follicle pool in women may, similar to that in mice, be amenable to renewal. Moving forward, the study of oogenesis in mammals, as well as the development of therapeutic strategies for the treatment of female infertility, should now take into account OSCs as natural precursor cells of oocytes 5, 6, 25 .
Although multiple methods have been reported for the successful propagation of OSCs in vitro, the relative purity of the initial population of cells retrieved from the ovaries varies on the basis of the isolation strategy used 2, 3, 9, 11, 23 . Antibody-based live cell-sorting strategies targeting an extracellular domain of the evolutionarily conserved germ cell marker, DEAD box polypeptide 4 (Ddx4) (refs. 26-28) , yield viable premeiotic germ cells from adult mouse ovaries that stably proliferate ex vivo and ultimately give rise to fertilizable oocytes in vivo 2, 3 . In addition to the Ddx4 antibody-based approach for OSC purification 2 , which has been rigorously and independently validated 3 , antibodies targeting an extracellular domain of the primitive germ cell marker interferoninduced transmembrane protein 3 (Ifitm3; refs. 29, 30) can also be used to isolate mouse OSCs 11 . We have confirmed the utility of this approach to isolate OSCs from adult mouse ovaries (D.C.W. and J.L.T., unpublished observations), which is important for reasons other than independent verification. Some scientists have questioned the use of antibodies against the C terminus of Ddx4 for isolating OSCs because the protein has historically been viewed, but never proven, to be a cytoplasmic protein in all germ cells [26] [27] [28] ; however, there is a clear precedent for externalized expression of Ifitm3 in primitive germ cells 31, 32 . Thus, any doubts regarding the validity of Ddx4 antibody-based OSC sorting are scientifically unsubstantiated simply on the basis of the fact that the same population of premeiotic germ cells can be isolated from postnatal mouse ovaries by using antibodies against either Ddx4 or Ifitm3 in cell-sorting protocols 2, 3, 11 . Because the utility of IFITM3 antibodies for purifying OSCs has not yet, at least to our knowledge, been tested with human ovarian tissue, the protocol detailed here focuses specifically on the use of Ddx4 (mouse; DDX4 in humans) as the target protein. Nonetheless, given the strong evolutionary conservation of mammalian germ cell development, it stands to reason that antibodies targeting an extracellular portion of IFITM3 would probably be successful for the immunological isolation of OSCs from human ovaries.
Although initial characterization of the Ddx4 gene in mice noted intracellular localization of the protein in oocytes by immunodetection 26 , whether or not the protein contains consensus transmembrane spanning or extracellular domains was not evaluated. Several years later, Wu and colleagues 2 performed a bioinformatic analysis of the Ddx4 protein sequence, resulting in the identification of a putative extracellular region at the C terminus of the protein.
In addition to confirming this prediction 33 , we have also compared the externalized Ddx4 amino acid sequence with other proteins across databases to determine whether this sequence is unique or whether other proteins containing a similar sequence might be expressed on the surface of OSCs. We found very little sequence homology to other proteins, known or predicted, which contain a cell-surface domain that would be recognized by the Ddx4 antibody used for sorting. The closest match of common sequence homology we found was between the Ddx4 target sequence and a small region of ATP-binding cassette subfamily C member 12 (Abcc12). However, the amino acid sequence in Abcc12 that shares any homology to the externalized domain of Ddx4 is restricted to an intracellular portion of the protein 34 . Thus, it is highly unlikely that the C-terminal Ddx4 antibody used by others and us to isolate OSCs cross-reacts with Abcc12 in living (non-fixed, non-permeabilized) cells.
In order to confirm the suitability of antibodies directed against the extracellular portion of Ddx4 for live-cell sorting, Wu and colleagues 2 also performed a visualization experiment using a Ddx4 antibody targeting the exposed C terminus, followed by a secondary antibody conjugated to large beads. This enabled visualization of the antibody-binding sites on the surface of Ddx4-positive cells. We repeated this visualization experiment essentially as described using dissociated mouse ovaries as starting material and found that antibodies against the C terminus, but not the N terminus, of Ddx4 bind to the surface of OSCs and not to isolated oocytes 3 . Nonetheless, because nonspecific binding of antibodies can be a problem in these types of immunolabeling experiments, further study was required to ensure that the antibody binding was specific to Ddx4.
To this end, we extensively validated the specificity of a C-terminal Ddx4 antibody for the purification of OSCs through FACS. By using two antibodies targeting Ddx4, one directed against the extracellular C-terminal portion and another targeting the cytoplasmic N terminus, we demonstrated that the cells to which the C-terminal antibody bound were Ddx4-positive and not a by-product of nonspecific binding 3 . The cell fraction obtained by the C-terminal Ddx4 antibody-based FACS approach yields a uniform population of cells that are less than 10 µm in diameter and positive for expression of Ddx4 along with many well-documented primitive germ cell markers, including PR domain containing 1 with ZNF domain (Prdm1), developmental pluripotency-associated 3 (Dppa3), Ifitm3 and telomerase reverse transcriptase (Tert, catalytic subunit of telomerase) 3 . Notably, once the OSCs are plated, many of the cells quickly expand in size (up to 20 µm in diameter), but they continue to actively proliferate for months while retaining a germline gene expression profile 3 .
antibody-based sorting, including the ability of the cultured cells to form oocytes in vitro 9 , we believe the use of TgOG2 mice for sorting of OSCs from ovarian tissue is not optimal for several reasons.
The most important of these is that expression of the endogenous Pou5f1 gene in germ cells fluctuates widely both in vivo and in vitro. During fetal ovarian development, Pou5f1 expression is maintained in primordial germ cells (PGCs) until the onset of meiotic entry (oocyte formation) and then downregulated, only to be activated once again after the differentiating germ cells have reached prophase of the first meiotic division [35] [36] [37] [38] . However, female germ cells continue to express Ddx4 during this entire time, even when Pou5f1 expression is essentially shut down, thereby highlighting a disconnect between the expression patterns of these two genes in developing germ cells. As one might expect, multiple populations of ∆PE-Pou5f1-GFP-expressing cells are actually observed in postnatal ovaries of TgOG2 mice. In addition to GFP-positive tetraploid cells (presumably small oocytes), a distinct population of much smaller GFP-positive diploid cells is detectable 9 . Of particular note, although GFP-positive cells obtained from TgOG2 mouse ovaries by FACS express germ cell markers as expected, many germ cell markers including Ddx4 are also readily detected in the cell fraction identified as negative for ∆PE-Pou5f1driven GFP expression 9 .
Given this information, we performed FACS analysis on dissociated TgOG2 mouse ovaries labeled with C-terminal Ddx4 antibody. We observed both GFP-positive and Ddx4-positive cell populations; however, we detected few, if any, cells that expressed both GFP and cell-surface Ddx4. Moreover, when transplanted into the ovaries of recipient wild-type mice, the isolated GFP-negative/Ddx4-positive cells generated GFP-positive oocytes (D.C.W. and J.L.T., unpublished observations) 6 , confirming both the identity of the isolated cells as oocyte progenitor cells and faithfulness of the transgene to be activated once oocytes are formed. Thus, although ∆PE-Pou5f1-GFP-positive ovarian cells appear to have at least some of the basic characteristics of OSCs when cultured in vitro, these cells probably represent a different developmental stage of germ cells compared with OSCs purified by antibody-based sorting. In this regard, it is notable that ∆PE-Pou5f1-GFP-positive cells isolated from TgOG2 ovaries lose expression of GFP shortly after initiation of ex vivo culture, while maintaining expression of germline and stem cell markers 9 . Whether this is due to transient expression of the ∆PE-Pou5f1-GFP transgene or perhaps to contamination with small oocytes that die off shortly after culture initiation is not known. However, because oocytes and OSCs exhibit a partially overlapping germline gene expression profile, any claims to study OSCs isolated on the basis of transgenic reporters must be certain that the cells under investigation are indeed OSCs and not immature oocytes.
A clearly illustrative example of this type of interpretational ambiguity recently arose in a study from Liu and colleagues 39 with a different transgenic reporter mouse line. In their attempt to find evidence of proliferative Ddx4-expressing cells in postnatal mouse ovaries, gonads were obtained from female offspring of Ddx4-Cre transgenic mice crossed with Rosa26 rbw/+ mice, which leads to a permanent genetic 'switch' in fluorescence from GFP (nonrecombined) to red, yellow or cyan fluorescent protein in any cell that has at some point transcriptionally activated the Ddx4 gene (recombined). Unfortunately, because both types of germ cellspremeiotic and postmeiotic-arise from more primitive germ cells that have already activated Ddx4 expression, the Ddx4-Cre recombinase-based switch in fluorescence is not specific for the identification of any one type of germ cell. In other words, OSCs and oocytes have an identical fluorescence pattern, which makes data interpretation in this type of study impossible unless additional steps are taken to unequivocally confirm the identity of the cells being evaluated. As a case in point, after crossing Ddx4-Cre transgenic mice with Rosa26 rbw/+ mice to obtain female offspring for analysis, Liu and colleagues 39 placed dispersed cell preparations obtained from ovaries of offspring at postnatal day 8 into culture. Over a subsequent 72-h period, recombined (red fluorescent, Ddx4-expressing) cells failed to proliferate, which prompted the conclusion that, contrary to many reports from us and others [1] [2] [3] 9, 11, 23 , mitotically active germ cells do not exist in postnatal mouse ovaries 39 . However, no effort was made by these investigators to confirm the identity of the recombined cells on which this conclusion was based. In fact, the relatively large size of the red fluorescent cells shown 39 , coupled with their inability to proliferate, suggests that the cells studied were actually small oocytes and not OSCs. Unfortunately, the interpretational problems with this experiment and its conclusions were only worsened by the absence of even a simple PCR-based gene expression profile showing the presence of markers of germ cells but not oocytes in the red fluorescent cells claimed as evidence against the existence of OSCs. These limitations, along with a lack of any experimental confirmation that the Ddx4 promoter fragment used to drive Cre expression is not 'leaky' (i.e., activated only in germ cells), combine to make this study and its interpretations far from conclusive.
Finally, crudely dispersed ovarian cell preparations and surface epithelial cell 'scrapings' have also been reported as a means to study fGSCs in vitro 23, [40] [41] [42] . It is important to note, however, that these methods invariably yield a heterogeneous cell population. Approaches such as these that do not target a specific cell type are therefore inherently problematic, as ovaries contain multiple stem cell populations [43] [44] [45] , none of which have been shown to possess the in vivo oocyte-forming capacity of OSCs. In addition, although germ cells derived from embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) differentiated in culture have been reported to form developmentally competent eggs after being recombined with fetal ovarian tissue and transplanted adjacent to adult ovarian tissue in vivo 46 , the differences between OSCs and germ cells derived from ESCs or iPSCs are many and substantial. Aside from the fact that OSCs are natural precursor cells for oocyte formation, and they accordingly perform this task without issue in adult ovarian tissue 2, 3 , ESC-and iPSC-derived germ cells require instructive cues from embryonic ovarian tissue to generate functional oocytes. In addition, oocyte formation after transplantation of ESC-or iPSCderived germ cells recombined with fetal ovaries occurs in a single synchronous wave 46 . This outcome mirrors that observed with transplanted embryonic PGCs but differs from the sustained oogenesis achieved with OSCs after transplantation into adult ovaries 2, 3 .
Summation
With this background information in mind, the following sections detail methods for Ddx4 antibody-based sorting of OSCs from adult human and mouse ovarian tissues, and for studying the properties and functions of purified OSCs in vitro and in vivo. A comprehensive schematic overview of the major protocol steps is shown in Figure 1 , whereas a detailed description of potential pitfalls and a guide for protocol troubleshooting are provided in Table 1 . It also should be mentioned that, although the protocols described herein are targeted at the purification and study of adult mammalian ovary-derived OSCs, we have tested and validated the C-terminal Ddx4 antibody-based FACS protocol for the purification of PGC-like cells from cultures of mouse ESCs after spontaneous differentiation 47 (D.C.W. and J.L.T., unpublished observations). Hence, the methods described here should be easily adaptable for those who use ESCs or iPSCs as a source of stem cells for germ cell derivation. Finally, our referral to the mitotically active germ cells that support oogenesis in adult ovaries as OSCs is intended to simply parallel the term SSCs, which is frequently used to describe the analogous population of mitotically active germ cells present in the adult testes that are responsible for spermatogenesis.
Experimental design
Isolation of OSCs from mouse ovaries or human ovarian cortex. Although OSCs can be isolated from ovaries of mice throughout the reproductive lifespan 48 , for initial validation of the protocol, we recommend using ovaries from mice between 6 and 8 weeks of age, as the ovarian tissue is more easily dispersed with collagenase. For the isolation of human OSCs, we have used freshly collected, vitrified-warmed and slow-frozen-thawed ovarian cortical tissue pieces with equal success. In addition, we have successfully isolated Dissociation of ovarian tissue. Both mouse and human tissues are dispersed into single-cell suspension using mechanical dissociation with collagenase. It should be noted that the enzymatic activity of collagenase varies considerably across suppliers and even across lots from a single supplier. As such, the dilution of collagenase needs to be carefully considered and adjusted as needed to reflect differences in units of enzymatic activity per mg of protein. Efficient retrieval and optimal viability of OSCs are both markedly affected by the amount of collagenase activity and length of exposure time of the ovarian tissue to collagenase for cell dispersion ( Table 1) .
Isolation of OSCs by FACS or MACS.
Both FACS and MACS have been described as methods for the isolation of OSCs from adult ovary tissue 2, 3, 11 . Although both methods use antibodybased detection of externally exposed protein epitopes on OSCs, in our experience, the cell population obtained by FACS (versus MACS) shows much greater viability and purity, with the latter demonstrated by a lack of oocyte markers in the final OSC fraction collected 3 . In addition, dead-cell exclusion and cell size-based inclusion can be performed simultaneously using FACS, further enhancing the viability and purity of the cell population obtained. Both FACS-and MACS-based isolation methods rely on the use of a C-terminal Ddx4 antibody to detect expression of this protein on the cell surface of OSCs. Although Ddx4 is expressed and detectable in both OSCs and oocytes in adult ovaries, OSCs express the C terminus of the protein on the cell surface, whereas Ddx4 is entirely cytoplasmic in oocytes 3 .
Alternative approaches and potential pitfalls. In addition to antibody-based isolation methods for the purification of OSCs from dissociated ovarian tissue 2,3,11 , OSCs have reportedly been isolated from ovaries using transgenic reporter mice 9 , as well as by crudely dispersing ovarian cell preparations, after which OSCs are selected by differential adhesion 23 . However, because of considerable pitfalls associated with interpretation of data from the study of cells obtained by these and other approaches (see INTRODUCTION, Non-immunological-based methods to isolate OSCs), it is highly recommended that antibody-based sorting methods be used to purify OSCs.
Analysis of freshly isolated OSCs.
Verification of the successful isolation of OSCs from ovarian tissue can be accomplished by simple PCR-based expression analysis of a panel of four genes that are widely accepted as primitive germ cell markers: Prdm1, Dppa3, Ifitm3 and Tert. If desired, a defined homogenous pool of somatic cells, such as fibroblasts, can be used as a negative control for sample comparison; however, fibroblasts from adult tissue (such as tail-tips) should be used rather than fibroblasts from an embryonic or fetal source. The presence of contaminating oocytes can simultaneously be ruled out by the assessment of several oocyte-specific markers not expressed in OSCs, including newborn ovary homeobox (Nobox), growth differentiation factor 9 (Gdf9) and zona pellucida glycoproteins 1-3 (Zp1-Zp3)(ref. 3) . It should be noted that of all of the OSC purification strategies reported to date, only the antibody-based FACS approach yields a purified population of homogenous cells free from contaminating oocytes and non-germline cell lineages. Notably, methods that do not exclude oocytes on the basis of the use of transgenic germline reporters that are not specific for only OSCs, or in the case of MACS oocytes that are dead or damaged (i.e., membrane compromised), can yield results that are ambiguous or impossible to accurately interpret (see INTRODUCTION, Non-immunologicalbased methods to isolate OSCs).
Establishment and propagation of OSCs in culture.
As is the case with cultured SSCs, mouse and human OSCs require the presence of FBS and a cocktail of growth factors in the culture medium for viability and sustained growth. Serum is undefined, with substantial lot-to-lot variability. In our experience, FBS lots intended for use with ESCs provide adequate support for mouse and human OSCs maintained in vitro. Nonetheless, it may be beneficial to batch-test FBS lots for optimal performance and outcomes. This can be easily done using ESC cultures, with serum lots that successfully maintain ESCs in an undifferentiated state identified as suitable for use with OSC cultures. Furthermore, although an underlying monolayer of somatic feeder cells is not absolutely required for the successful establishment of mouse or human OSCs in vitro, the initial rate of proliferation is greatly enhanced using a coculture system in which freshly isolated OSCs are seeded onto mitotically inactivated mouse embryonic fibroblasts (MEFs). In our experience, optimal outcomes are achieved if MEFs are replaced every 2 weeks, and, during the initial establishment of the OSC cultures, the cells are passaged onto new MEFs every 10-12 d.
Analysis of in vitro-derived oocytes. After establishment in culture, a subset of mouse and human OSCs spontaneously initiate a differentiation program and form immature oocytes immediately after each passage of the cells that persists for up to 3 d (Fig. 2) . The OSC-derived oocytes are non-adherent (released into the culture medium) and are easily distinguished from the cells in culture on the basis of their size and morphology. Oocytes can be removed from the culture medium by selective aspiration and analyzed for expression of oocyte-specific markers by PCR or immunofluorescence-based cytochemistry ( Fig. 2; ref. 3). In our experience, the number of oocytes produced each day of the 3 d after passage is consistent from passage to passage, and it can be used as a quantitative assessment of the rate of oocyte production from OSCs maintained under different experimental conditions in vitro 49 .
Transplantation of human OSCs into human ovary tissue and xenografting.
For transplantation and fate-mapping experiments, OSCs can be readily transformed to express a fluorescence reporter, such as GFP, using standard viral transduction protocols. The reagents used to produce retrovirus are included in the Reagents section. The use of retroviruses has a distinct advantage for transduction of OSCs cocultured with MEFs, as retroviruses generally target only proliferating cells. As the feeder cells have been mitotically inactivated, the virus does not infect these cells. Once the protocol is performed, resultant GFP-expressing OSCs can be purified by FACS and used directly for injection or subsequently propagated without the loss of GFP expression. After stable integration of GFP, expanded human OSCs can be directly injected into small pieces (in general, pieces 2 mm long × 2 mm wide × 1 mm thick work well) of outer cortex obtained from ovaries of reproductive age women. The injected cortical samples can then be transplanted subcutaneously into immunocompromised mice. Successful xenografting occurs most frequently when the tissue is sutured in close proximity to the cutaneous vasculature. Retrieval of the grafts at 1-2 weeks after transplantation is sufficient for the subsequent immunodetection of GFP-positive human oocytes contained within histologically normal follicles comprising GFP-negative granulosa cells ( Fig. 3; ref. 3).
Intraovarian transplantation of mouse OSCs into syngeneic recipient mice. Using microdissection scissors to open the ovarian bursa surrounding each ovary of the recipient wild-type female mice, GFP-expressing mouse OSCs can be directly microinjected into the exposed ovarian tissue at several sites. Similar to what is observed after the delivery of GFP-expressing human OSCs into human ovarian cortical tissue, GFP-positive mouse oocytes are detectable in the recipient ovaries, enclosed within wild-type somatic cells as follicles, within 1-2 weeks (Fig. 3) . These chimeric follicles progress through all stages of maturation, and they are responsive to gonadotrophic hormone stimulation, resulting in ovulation of the enclosed GFP-expressing oocytes (Fig. 4) . These oocytes can be retrieved from the oviducts and embryonic development can be monitored after in vitro fertilization (IVF) using wild-type spermatozoa (Box 1 and Fig. 4 ; ref.
3). In parallel, mating trials can be conducted by housing wild-type female mice after intraovarian injection of GFP-expressing OSCs with wild-type male mice of proven fertility. Conventional PCR-based genotyping is then performed to determine whether the oocyte fertilized in vivo to produce a given offspring was derived from the recipient (wild-type) or from the transplanted OSCs (GFP-positive). For these types of functional tests, OSCs isolated from ovaries of wildtype female mice and transduced with GFP, or OSCs isolated from ovaries of transgenic female mice with documented expression of GFP in germ cells (for example, TgOG2), can be used to track cell fate after transplantation into wild-type recipients. It should be noted that, although a prior report of offspring production from transplanted mouse OSCs used chemotherapy-conditioned female mice as recipients 2 , we have found that mouse OSCs successfully engraft and produce functional oocytes after transplantation into ovaries of female mice without the need for any prior conditioning protocol 3, 24 .
Box 1 | IVF of OSC-derived eggs after superovulation
This is a 5-d procedure that is performed after transplantation of mouse OSCs bearing a traceable marker gene into ovaries of adult wild-type female recipient mice (Step 30C); we recommend that the injected cells be allowed to engraft and differentiate for at least 4 weeks before performing this procedure. 1. Begin by injecting 5 IU of PMSG solution (100 µl of prepared stock; depending on age and weight of the females, this dose can be increased to 10 IU) using an insulin syringe into the peritoneal cavities of female mice that have received intraovarian OSC transplants.
2. Approximately 46 h later, inject 5 IU of hCG solution (100 µl of prepared stock; depending on age and weight of the females, this dose can be increased to 10 IU) into the peritoneal cavities of the same mice. 3. Add 1 ml of HTF medium to a center-well organ culture dish to be used for sperm collection (label this as 'sperm collection dish'). 4. For each female mouse, add 500 µl of HTF medium to a center-well organ culture dish to be used for IVF (label this as 'IVF dish'). 5. For each female mouse, place five separate 40-µl droplets of HTF medium into a 60-mm culture dish to be used for washes; gently cover each HTF droplet in mineral oil (label this as 'wash dish'), ensuring that the droplets remain separate. 6. For each female mouse, place five separate 40-µl droplets of KSOM-AA medium into a 60-mm culture dish to be used for culture; gently cover each KSOM-AA droplet medium with mineral oil (label this as 'Culture Dish'), ensuring that the droplets remain separate. 7. Place the labeled dishes prepared in steps 3-6 in a humidified tissue culture incubator at 37 °C under 5% CO 2 -95% air. 8. At 13 h after hCG injection, euthanize an adult male mouse according to your institutional guidelines (we use i.p. injection of Avertin (200 mg kg − 1 ), followed by decapitation). 9. Dissect out the cauda epididymis and vas deferens, taking care to remove any adherent fat, and place the tissue into the sperm collection dish. 10. Use an insulin syringe needle to cut open the cauda epididymis. 11. By using sterile forceps, gently squeeze the spermatozoa from the vas deferens through the opened cauda epididymis; remove tissue and discard. 12. To capacitate the extruded spermatozoa, place the sperm collection dish containing the spermatozoa in a humidified tissue culture incubator at 37 °C under 5% CO 2 -95% air for 1 h. 13. After 1 h, add ~10 µl of capacitated spermatozoa to the HTF medium in the IVF dish and return the dish to incubator. 14. At this time, prepare a 60-mm culture dish containing 1 ml of HTF medium and label it as 'ovary/oviduct holding dish'; at this time, for each female mouse label a separate empty dish as 'COC dish' for collection of ovulated COCs from the oviducts. 15 . At 14 h after hCG injection (once the sperm capacitation step is completed), euthanize the transplanted female mice according to the user's institutional guidelines (we use i.p. injection of Avertin (200 mg kg − 1 ), followed by decapitation). 16. Quickly remove the ovaries and attached oviducts from the body cavity of each mouse and place them into the ovary/oviduct holding dish containing HTF medium. 17. Transfer one ovary and attached oviduct to an empty COC dish; use an insulin syringe needle to open the ampulla (bulge) of the oviduct to release the superovulated COCs. Repeat the procedure with oviducts from each ovary in a separate dish.  crItIcal step To facilitate the collection of the COCs released from the oviducts, this step should be performed in an empty dish (no medium); the medium associated with the tissue when transferred from the ovary/oviduct holding dish to the COC dish is of sufficient volume to perform this step and maximize COC retrieval. 18. Identify and transfer the COCs from the COC dish to 500 µl of HTF medium in the IVF dish (previously prepared in step 4) containing the capacitated sperm (previously prepared in step 3 ! cautIon Informed consent must be obtained from human subjects who donate ovarian tissue for research purposes, and proposed experiments must conform to all required institutional, local and/or national policies and regulations for human subjects research.
• (ii) Place the cryovial containing the sample into a Dewar container into which liquid nitrogen has been added. ! cautIon Take adequate safety precautions when working with liquid nitrogen. (iii) Warm the thawing solution contained in a 50-ml tube provided in the kit to 37 °C in a water bath; water temperature should be verified and recorded using a calibrated thermometer. ! cautIon Take adequate safety precautions when working with liquid nitrogen.
(iv) Warm the cryovial by rubbing between hands until freezing medium has thawed (~2-3 min).
(v) By using a pair of sterile forceps, remove the pieces of ovarian tissue from the cryovial and place into well no. 1 of the six-well plate containing the thaw medium (prepared above). Keep the sterile forceps for further use in sequentially transferring the pieces of tissue from one well to another as described below. (i) Just before ovarian tissue collection, prewarm an oribital shaker to 37 °C. Carefully dissect the ovaries from female mice, taking care to remove the attached fat pad, bursa and oviduct from each ovary.  crItIcal step Tissue dispersion into single-cell suspension is easier using ovaries from younger adult animals (6-8 weeks of age), which may help to improve overall OSC yield. In our experience, optimal OSC retrieval is obtained using four ovaries pooled as a single sample, and retrieval efficiency is not improved further with additional ovaries added to the sample. ? trouBlesHootInG (ii) By using a scalpel blade or mincing scissors, mince the ovaries into slurry in 0.5 ml of collagenase/DNase I solution (Reagent Setup) in a glass tissue culture dish.
? trouBlesHootInG (iii) By using a 5-ml glass serological pipette, rinse the slurry to the bottom of the dish with 2.5 ml of collagenase/DNase I solution and collect the slurry by placing the entire 3 ml of solution into a 15-ml conical tube. ? trouBlesHootInG (viii) Filter the cell suspension through a 100-µm nylon mesh cell strainer, collecting the filtrate into a new 15-ml conical tube.
? trouBlesHootInG (ix) Add 10 ml of warm HBSS to the conical tube containing the strained cell suspension (from Step 8), and centrifuge the tube at 300g for 5 min at room temperature, with the centrifuge brake turned off (brake rate set to 0; this is very important so as to minimize disruption or dislodging of the cell pellet).
? trouBlesHootInG (x) After centrifugation, carefully decant the liquid and save the cell pellet. Take care to remove as much of the supernatant as possible without disturbing the cell pellet (this can be done by gently touching the opening of the inverted 15-ml conical tube on sterile gauze). Proceed with Step 3.  crItIcal step Aspiration of the liquid, rather than gentle decanting, is not recommended as the vacuum suction created by aspiration can dislodge or disrupt the cell pellet and result in cell loss. Step 2B(ix) into the 15-ml conical tube containing the strained cell suspension from Step 2B(ix). (xii) Centrifuge the strained ovarian cell suspension (in the 15-ml conical tube) at 300g for 5 min at room temperature with the brake on the centrifuge turned off (brake rate set to 0). ? trouBlesHootInG (xiii) After centrifugation, carefully decant the liquid and save the cell pellet. Take care to remove as much of the supernatant as possible without disturbing the cell pellet (this can be done by gently touching the opening of the inverted tube on sterile gauze). Proceed with Step 3.  crItIcal step We do not recommend aspiration of the liquid, rather than gentle decanting, as the vacuum suction created by aspiration can dislodge or disrupt the cell pellet and result in cell loss.
3| By using a sterile 5-ml glass serological pipette, gently resuspend the cell pellet in 4 ml of warm HBSS. Bring the volume to 10 ml with warm HBSS.
4|
Centrifuge the cell suspension at 300g for 5 min at room temperature with the brake on the centrifuge turned off (brake rate set to 0). ? trouBlesHootInG 5| After centrifugation, carefully decant the liquid and save the cell pellet. Take care to remove as much of the supernatant as possible without disturbing the cell pellet (this can be done by gently touching the opening of the inverted vial on sterile gauze).  crItIcal step All prior steps are performed at 37 °C or room temperature, as indicated, for optimal enzymatic digestion and centrifugation. Subsequent steps are performed at 4 °C. ? trouBlesHootInG preparation of cells for antibody labeling • tIMInG 90 min 6| Gently resuspend the cell pellet obtained in Step 5 in 500 µl of cold antibody blocking/dilution solution. Label this tube as 'sample' and place it on ice for 20 min. ! cautIon All incubations on ice should be performed using fresh (non-melted) ice to minimize cell damage (all tubes containing cells should be in the ice phase and not exposed to the ice-melted ice water interface). ? trouBlesHootInG 7| Set the centrifuge to 4 °C. Perform this step when the tube of cells is first placed on ice in Step 6 to give ample time for the centrifuge to cool to 4 °C. The brake speed should be set to 9 or maximum.
8| Label a 15-ml conical tube as 'negative control', and label another 15-ml conical tube as 'secondary antibody only' .
9|
Add 100 µl of cell suspension from the sample tube (Step 6) to the negative control and secondary antibody only tubes. Place the tubes on ice.
10| Bring the remaining 300 µl of cell suspension in the sample tube to 10 ml with cold HBSS. Centrifuge the suspension at 300g for 5 min at 4 °C. ? trouBlesHootInG
11|
Remove the sample tube from the centrifuge and discard the supernatant, being careful not to disturb or dislodge the cell pellet.  crItIcal step Ensure that as much supernatant as possible is removed as any residual supernatant volume will dilute the final primary antibody concentration at the next step; we recommend that the sample tube be gently inverted over sterile gauze to blot, and then any residual supernatant volume should be carefully collected away from the cell pellet with a small pipette tip. ? trouBlesHootInG 12| Gently resuspend the cell pellet in 100 µl of prepared primary antibody solution (Reagent Setup).
? trouBlesHootInG
13|
Place the suspension on ice and incubate it for 20 min.
14|
Bring the resuspended cell sample mixed with primary antibody in the 'Sample' tube to a total of 10 ml with cold HBSS. Centrifuge the mixture at 300g for 5 min at 4 °C. ? trouBlesHootInG 15| Remove the sample tube from the centrifuge and carefully discard supernatant. Depending on the amount of initial starting material (ovarian tissue), a cell pellet may or may not be readily visible with the naked eye at this time.
16| Gently resuspend the sample tube cell pellet in 10 ml of cold HBSS. Centrifuge the suspension at 300g for 5 min at 4 °C. At this time, centrifuge the cells in the secondary antibody only tube (from Step 9). Discard the supernatants. ? trouBlesHootInG Isolation or enrichment of oscs 17| If you are using FACS to isolate OSCs, follow option A. If you are using MACS to enrich for OSCs, follow option B.  crItIcal step We highly recommend the use of FACS instead of MACS for isolation of OSCs, as we have found that OSC preparations obtained by MACS are often contaminated with small oocytes 3 . In addition, FACS offers the user the advantages of damaged or dead cell exclusion and homogenous cell-size selection. If, however, the user does not have access to FACS facilities, MACS can be used to obtain OSCs, although subsequent use and analysis of the cells should take into account the possibility of oocyte contamination.  crItIcal step To establish and expand freshly isolated OSCs on MEFs, remove the MEF culture medium from a previously seeded MEF feeder cell plate (Equipment Setup) and place the resuspended OSCs into the well containing the MEFs.
19|
Place the cells into a humidified tissue culture incubator at 37 °C, maintained under 5% CO 2 -95% air. Freshly isolated OSCs will take ~5-7 d to establish ('plate down') and begin colony formation, although actively dividing germ cell colonies (Fig. 5) may not become apparent to the naked eye for 2 weeks or more. During this time, the culture medium should be refreshed by adding several drops of fresh OSC culture medium to the wells every other day.  crItIcal step Do not attempt to remove culture medium or passage the cells during this initial growth phase.
20|
Allow cells to form visible colonies (human OSCs) or reach 90% confluence (mouse OSCs) before passaging. Human OSC cultures generated from freshly isolated cells are ready to pass when they have established 'proliferative centers' (clusters of cells). The cells are generally elongated in appearance, and they may vary in size, possibly related to their individual state of differentiation. Allowing the colony size to become too large will result in increased cell death. ? trouBlesHootInG 21| For passage, remove the spent culture medium and place it into a 15-ml conical tube labeled with the name of the OSCs (for example, mouse or human and sort date) and the new passage number (the old passage number plus 1). Set it aside.  crItIcal step Save the remaining spent culture medium and use it to neutralize trypsin after passage (Step 23); moreover, nonadherent OSCs will be present in the spent culture medium and thus it should not be discarded. 22| Gently passage by adding 0.1 ml of 0.05% (wt/vol) trypsin-EDTA solution to the well containing the cells. Human OSCs should be passaged in clusters (do not attempt to disrupt human OSCs into a single-cell suspension), whereas mouse OSCs should be passaged as a single-cell suspension. ! cautIon Watch this step carefully so as to not 'overtrypsinize' the cells (especially human OSCs); also, do not resuspend human OSCs into a single-cell suspension for passage.
? trouBlesHootInG  pause poInt Although the use of trypsin for the initial dissociation of ovarian tissue to obtain cell suspensions for OSC sorting is unnecessary and strongly discouraged in order to minimize damage to the cell surface exposed protein epitopes required for successful antibody-based FACS or MACS, once OSCs have been purified and established in culture, a brief exposure to very low amounts of trypsin (0.05%, wt/vol) for the purpose of cell passage is fine.
23|
To neutralize the trypsin, tilt the plate to a 45° angle and add spent medium (from Step 21) to the top of the well. Rinse all contents of the well to the bottom. In established OSC cultures (mouse and human), spontaneous oocyte formation (oogenesis) occurs within 1-3 d after each passage (Fig. 2) . At the seeding densities recommended above, we routinely observe the formation of ~100-300 oocytes in each well 3 . The process of spontaneous oogenesis subsides as the cells reach maximum density again. The oocytes formed are released into the medium, and they can be easily distinguished from OSCs on the basis of size and morphology 3 . If in vitro oogenesis is desired as an endpoint of study, the user should follow option A below. In addition to analysis of oocyte formation in vitro, the fate of OSCs carrying a traceable marker gene (for example, GFP) after injection into ovarian tissue can also be studied using transplantation models reported recently 3 . To perform such studies using human OSCs, follow option B below; if you are using mouse OSCs, follow option C below. For monitoring the fate of human OSCs injected into adult human ovarian cortical tissue, the OSCs need to be engineered to carry a traceable marker gene that will be expressed in oocytes formed from these cells. For our experiments, we use retroviral transduction as a means to introduce stable expression of GFP in human OSCs before injection 3 . Briefly, transfect 1 µg of pBabe-Gfp vector DNA into the Platinum-A retroviral packaging cell line using Lipofectamine according to the manufacturer's guidelines. Seventy-two hours later, transduce actively dividing OSC cultures using fresh viral supernatant in the presence of 10 µg ml − 1 polybrene. After 1 week of propagation, purify the GFP-expressing cells by FACS. Expand the purified cells for an additional 1-2 weeks, re-sort by FACS and repeat expansion of the GFP-expressing cells for 1 additional week before the experiment.  crItIcal step To monitor the fate of mouse OSCs injected into wild-type adult mouse ovaries, the OSCs must carry a traceable marker gene that will be expressed in oocytes formed from these cells. We have used two different approaches with equal success. The first uses OSCs purified from ovaries of adult female TgOG2 (∆PE-Oct4-Gfp) transgenic mice, which generate oocytes with GFP expression after introduction into the wild-type adult mouse ovaries 6 (D.C.W. and J.L.T., unpublished observations). If such mice are not available to the user, retroviral transduction can be used as a means to introduce stable expression of GFP in wild-type mouse OSCs before injection 3 . This is performed as described above for transduction of human OSCs. We use 2% (wt/vol) Avertin prepared in sterile PBS (0.03 ml per g of body weight) injected into the peritoneal cavity in a total volume of 0.1 ml. If desired, prophylactic analgesics (such as buprenorphine; 0.05-0.1 mg kg − 1 , s.c. in a 20-µl volume) can be provided to mice 30 min before surgery and for 72 h after surgery (and longer as may be needed after consultation with institutional veterinary staff). (viii) Prepare the incision site by removing fur and cutting the skin along the dorsal midline (~20 mm).
(ix) Directly suture the OSC-injected human ovarian cortical tissue in close proximity to the cutaneous vasculature under the skin flap. (x) Close the incision site with sutures and allow the mouse to recover according to your institutional guidelines. We place the mice in clean cages on warming trays set to 37 °C. Once the mice are fully awake (~30 min), they are monitored for an additional 30 min afterward to ensure that each animal regains alertness and the ability to move freely and easily (for example, to reach food and water), and that animals show minimal discomfort resulting from the surgery. After the mice are transferred back to housing rooms, they are assessed at least twice daily for the first 3 d after surgery, once daily afterward for 4 d and (depending on the experimental outcome) every 3 d after the first week of surgery for signs of complications, discomfort or infections related to the surgery. (vii) While holding the ovary with forceps, insert the micropipette tip into the ovary and inject the cell suspension into the ovary using the foot pedal supplied with the PicoPump. (viii) Once the entire volume has been injected, allow the ovary to settle back into the body cavity and close incision site with sutures. (ix) Allow the mouse to recover as your institutional animal care guidelines. We place the mice in clean cages on warming trays set to 37 °C. Once the mice are fully awake (~30 min), they are monitored for an additional 30 min afterward in order to ensure that each animal regains alertness, regains the ability to move freely and easily (for example, reach food and water) and shows minimal discomfort resulting from the surgery. After the mice are transferred back to housing rooms, they are assessed at least twice daily for the first 3 d after surgery, once daily afterward for 4 d and (depending on the experimental outcome) every 3 d after the first week of surgery for signs of complications, discomfort or infections related to the surgery. (x) After intraovarian transplantation of OSCs, the recipient mice can be used for analysis of OSC-derived oocyte formation by immunohistochemical detection of GFP in oocytes contained in follicles 3 , or IVF-based studies of OSC-derived oocytes (Box 1; ref.
3); alternatively, they can be placed in mating trials for evaluation of germline transmission of the OSC reporter gene to offspring 2, 12, 24 .
? trouBlesHootInG Troubleshooting advice can be found in table 1. Increase centrifugation from 300g to 600g to improve pelleting of the cells; perform all centrifugation steps using 15-ml conical vials to improve cell pelleting (do not use round-bottom tubes); when removing supernatants after centrifugation, do not use suction, as this can dislodge/disrupt the pellet and result in cell loss 11, 12 When discarding supernatant before adding primary antibody solution, make sure <100 µl of supernatant remains, as this additional volume will dilute the primary antibody; adjust the amount of primary antibody (for a final concentration of 1:10-1:20) accordingly If cell viability before and during FACS is high but reduced after sorting, change the collection method; decrease surface tension by increasing the amount of medium in the collection tube into which the cells are collected; do not collect cells into plates, as cells will lyse on impact. We recommend sorting into 1.5-ml Eppendorf tubes containing 1 ml of medium and located as close to the emitter as possible
The final cell fraction prepared for FACS will contain cells of multiple sizes as well as debris from the tissue digestion; an experienced FACS technician should be consulted to distinguish between cell fragments and viable small cells (the desired cell population is very small, 10 µm or less in diameter) and include a viability dye, such as DAPI or propidium iodide 17A(vi), FACS Avoid bubbles in the FACS collection tube, as this increases surface tension, which can lyse cells being collected 17 During the antibody blocking and labeling steps, which are performed on ice, "wet" ice (melted ice water with ice) has a much lower temperature than fresh ice and is lethal to cells; when performing antibody blocking and labeling steps, use fresh ice and ensure that all tubes are maintained only in the upper ice phase The fate of transplanted OSCs can be monitored using 'traceable' OSCs, such as those expressing GFP either through retroviral transduction of wild-type OSCs or purification of OSCs from ovaries of transgenic mice with documented germ cell-specific reporter gene expression. Mouse OSCs expressing GFP can be transplanted into the ovaries of young adult wild-type syngeneic recipients, and the subsequent formation of GFPpositive oocytes contained within follicles composed of wild-type (host-derived) somatic granulosa cells can be detected by conventional immunohistochemical protocols ( Fig. 3; refs. 2,3) . Moreover, after superovulation with exogenous gonadotrophins and retrieval of eggs from the oviducts, fertilization competency and embryonic developmental potential of OSC-derived (GFP-expressing) oocytes can be performed after IVF (Box 1 and Fig. 4; ref. 3). Alternatively, female mice transplanted with OSCs can be monitored in natural mating trials for giving birth to offspring carrying the traceable gene of interest 2, 12, 24 (J.L.T. laboratory, unpublished observations). The ability of human OSCs to generate new oocytes that then participate in follicle formation in adult human ovary tissue can be determined by injecting human ovarian cortical tissue with human GFP-expressing OSCs. Within 1-2 weeks of s.c. grafting of the injected tissue into immunocompromised (NOD/SCID) female mice, GFP-positive human oocytes can be found localized within primordial and primary follicles throughout the tissue ( Fig. 3;  ref. 3). To verify that the GFP-positive cells within these follicles are oocytes, dual-immunofluorescence detection of GFP with oocyte-specific gene products, such as the meiotic diplotene-stage germ cell marker Y-box binding protein 2 (YBX2) (refs. 53,54) or the transcriptional regulator LIM homeobox 8 (LHX8) (ref. 55) , can be used to reveal dual-positive oocytes 3 . Finally, injection of human GFP-expressing OSCs into human ovarian cortical tissue placed in multistep culture systems, which have been shown to support formation and maturational development of follicles entirely ex vivo 56, 57 , provides a means to study human oogenesis and folliculogenesis under defined conditions without the need for a 'foreign' (mouse) host 5 .
Finally, we would like to note that use of the terms 'Ddx4-positive' and 'Ddx4-negative' when referring to the fractions of cells obtained following FACS-based immunological detection of the C-terminus of Ddx4 protein in dispersed ovarian cells is not intended to indicate the absence of Ddx4 gene expression in all cells that lack externalized Ddx4 protein. As a case in point, small oocytes express the Ddx4 gene and contain Ddx4 protein, but the protein is completely cytoplasmic. Accordingly, and unlike OSCs, viable (non-fixed, non-permeabilized) oocytes show no interaction with antibodies against the C-terminus of Ddx4 (ref. 3) . While oocytes would be considered 'Ddx4-negative' in the context of the antibody-based OSC sorting protocols described herein, oocytes are nonetheless 'Ddx4-positive' in the general context of Ddx4 gene expression. We therefore propose that viable cells identified as reactive with the C-terminal Ddx4 antibody (i.e., OSCs) should be referred to as 'ecDdx4-positive' (for 'extracellular Ddx4-positive'), and the remaining cells lacking externalized expression of Ddx4 protein, which can include small oocytes, should be referred to as 'ecDdx4-negative' . Use of this terminology will help minimize confusion in future studies of germ cells at different stage of development, all of which express the Ddx4 gene but differ in their ability to be separated and identified on the basis of externalized Ddx4 protein. autHor contrIButIons D.C.W. and J.L.T. contributed equally to the development and validation of the protocols described, and the preparation of this article for publication.
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